• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

UF Treatment Goals


Dr Al-Hendy briefly explains how he determines treatment goals during initial workups for patients with UF.

Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP: Treatment goals for patients with uterine fibroids is variable. The most important factor is the age of the patient, but there are many other factors, like severity of symptoms and what kind of symptoms. Many patients have heavy menstrual bleeding, but for that subgroup that I mentioned, about 15 to 20%, they mainly complain about bulk symptoms and not so much about the bleeding. This is all important, but the age is very important. Why? Because age also connects to fertility.

I’m at the University of Chicago, so I see a lot of our own students. They are very young, most of them aren’t ready to start a family, many of them might not even be in a relationship. They want to take care of their fibroid symptoms, but they want to preserve their fertility. [That’s different from] somebody who has a family, maybe already had a tubal ligation, is in her early 40s, and has different goals—mainly controlling symptoms, because fertility is not an issue for her. That group is also very close to menopause, with an average age of 52 years. It’s very common in perimenopause—the 10 years before menopause, let’s say 42 to 52—with a group that’s approaching menopause, to support them. Once you hit menopause, this issue will be self-resolved. Fibroids tend to grow, shrink, and melt away at menopause, so the age of the patient and her fertility interest are the most important.

This transcript has been edited for clarity.

Related Videos
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Video 3 - "Harnessing Prescription Drug Therapeutics as Monotherapy and Adjunct Therapy"
Video 8 - "Demographic Differences That Impact Care"
Video 7 - "Gaps in Diabetes Education and Self Efficacy"
Video 6 - "Developing Reimbursement Models for Digital Therapeutics"
Video 5 - "Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics"
Video 2 - "Bridging Care Gaps with Prescription Digital Therapeutics"
Video 1 - "Overview of Prescription Digital Therapeutics and Impact on Clinical Practice"
Video 4 - "Payer Challenges in Evaluating Digital Therapeutics"
Video 3 - "Industry Collaboration in Shaping Digital Therapeutics Standards"
© 2024 MJH Life Sciences

All rights reserved.